ADMA Biologics Inc (ADMA) Expected to Announce Quarterly Sales of $6.68 Million

Equities analysts expect ADMA Biologics Inc (NASDAQ:ADMA) to post sales of $6.68 million for the current quarter, Zacks reports. Two analysts have provided estimates for ADMA Biologics’ earnings. The lowest sales estimate is $5.50 million and the highest is $7.85 million. ADMA Biologics reported sales of $3.33 million in the same quarter last year, which would suggest a positive year over year growth rate of 100.6%. The business is expected to report its next earnings results on Friday, February 23rd.

According to Zacks, analysts expect that ADMA Biologics will report full-year sales of $6.68 million for the current financial year, with estimates ranging from $16.30 million to $18.61 million. For the next year, analysts anticipate that the business will report sales of $38.15 million per share, with estimates ranging from $28.31 million to $48.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow ADMA Biologics.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Friday, November 3rd. The biotechnology company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $1.10. ADMA Biologics had a negative return on equity of 76.26% and a negative net margin of 35.00%.

Several research analysts recently issued reports on the company. Maxim Group reissued a “buy” rating and issued a $8.00 price objective (down previously from $13.00) on shares of ADMA Biologics in a research note on Monday, December 11th. Raymond James Financial raised ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 price objective on the stock in a research note on Tuesday, November 14th.

ADMA Biologics (ADMA) opened at $3.80 on Friday. ADMA Biologics has a 52 week low of $2.01 and a 52 week high of $5.44. The company has a quick ratio of 1.35, a current ratio of 2.36 and a debt-to-equity ratio of 2.26.

In other news, Director Eric I. Richman acquired 25,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The shares were bought at an average price of $2.15 per share, with a total value of $53,750.00. Following the completion of the purchase, the director now directly owns 31,300 shares in the company, valued at $67,295. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Adam S. Grossman bought 485,000 shares of the stock in a transaction on Thursday, November 9th. The shares were bought at an average price of $2.15 per share, with a total value of $1,042,750.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 526,500 shares of company stock worth $1,131,975. 60.44% of the stock is owned by insiders.

A hedge fund recently raised its stake in ADMA Biologics stock. Iguana Healthcare Management LLC boosted its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 565,000 shares of the biotechnology company’s stock after buying an additional 415,000 shares during the period. Iguana Healthcare Management LLC owned 2.19% of ADMA Biologics worth $1,740,000 as of its most recent filing with the Securities & Exchange Commission. 32.78% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was published by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with's FREE daily email newsletter.

Leave a Reply